(Loss) Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended	3 Months Ended				12 Months Ended
	May 30, 2015	Mar. 03, 2018	Dec. 02, 2017	Sep. 02, 2017	Jun. 03, 2017	Mar. 03, 2018	Mar. 04, 2017	Feb. 27, 2016
Numerator:
(Loss) income from continuing operations attributable to common stockholders- basic and diluted						$ (349,532)	$ 4,080	$ 102,088
Income (loss) from discontinued operations attributable to common stockholders-basic and diluted						1,293,002	(27)	63,377
Income attributable to common stockholders-basic and diluted						$ 943,470	$ 4,053	$ 165,465
Denominator:
Basic weighted average shares						1,049,628	1,044,427	1,024,377
Outstanding options and restricted shares, net (in shares)							16,399	17,985
Diluted weighted average shares						1,049,628	1,060,826	1,042,362
Basic (loss) income per share:
Continuing operations		$ (0.46)	$ (0.02)	$ 0.18	$ (0.03)	$ (0.33)	$ 0.00	$ 0.10
Discontinued operations		1.19	0.10	(0.02)	(0.04)	1.23	0.00	0.06
Net basic income per share		0.73	0.08	0.16	(0.07)	0.90	0.00	0.16
Diluted income (loss) per share:
Continuing operations		(0.46)	(0.02)	0.18	(0.03)	(0.33)	0.00	0.10
Discontinued operations		1.19	0.10	(0.02)	(0.04)	1.23	0.00	0.06
Net diluted income per share		$ 0.73	$ 0.08	$ 0.16	$ (0.07)	$ 0.90	$ 0.00	$ 0.16
Stock options
Antidilutive securities excluded from computation of income per share
Shares excluded from the computation of diluted income per share						7,484	3,200	3,464
8.5% convertible notes due May 2015
Convertible notes due 2015
Convertible notes amount	$ 64,089
Debt instrument, stated interest rate (as a percent)	8.50%
Shares issued for EnvisionRx acquisition (in shares)	24,762